Preclinical assessment of a pluripotent cell therapy for treatment of Parkinson's Disease
Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Standard
Preclinical assessment of a pluripotent cell therapy for treatment of Parkinson's Disease. / Kirkeby, A.
In: Toxicology Letters, Vol. 350, No. Supplement, 2021, p. S37.Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Harvard
Kirkeby, A 2021, 'Preclinical assessment of a pluripotent cell therapy for treatment of Parkinson's Disease', Toxicology Letters, vol. 350, no. Supplement, pp. S37. https://doi.org/10.1016/S0378-4274(21)00331-3
APA
Kirkeby, A. (2021). Preclinical assessment of a pluripotent cell therapy for treatment of Parkinson's Disease. Toxicology Letters, 350(Supplement), S37. https://doi.org/10.1016/S0378-4274(21)00331-3
Vancouver
Kirkeby A. Preclinical assessment of a pluripotent cell therapy for treatment of Parkinson's Disease. Toxicology Letters. 2021;350(Supplement):S37. https://doi.org/10.1016/S0378-4274(21)00331-3
Author
Bibtex
@article{dfcae3a33e1c4db7bfe03c4cd982b7b3,
title = "Preclinical assessment of a pluripotent cell therapy for treatment of Parkinson's Disease",
author = "A. Kirkeby",
year = "2021",
doi = "10.1016/S0378-4274(21)00331-3",
language = "English",
volume = "350",
pages = "S37",
journal = "Toxicology Letters",
issn = "0378-4274",
publisher = "Elsevier Ireland Ltd",
number = "Supplement",
}
RIS
TY - ABST
T1 - Preclinical assessment of a pluripotent cell therapy for treatment of Parkinson's Disease
AU - Kirkeby, A.
PY - 2021
Y1 - 2021
U2 - 10.1016/S0378-4274(21)00331-3
DO - 10.1016/S0378-4274(21)00331-3
M3 - Conference abstract in journal
VL - 350
SP - S37
JO - Toxicology Letters
JF - Toxicology Letters
SN - 0378-4274
IS - Supplement
ER -
ID: 285183303